The FDA has granted Abeona Therapeutics Fast Track status to the Gene Therapy trial to treat Sanfilippo Syndrome Type IIIA. ... Learn more
News
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference
Exciting 30-day trial data has been released by Abeona Therapeutics. Highlights include Gene Therapy has been well-tolerated in low-dose Cohort of first 3 subjects, there has been a significant reduction of Heparan Sulfate in urine and cerebral ... Learn more
Gene Therapy Trial Shows Encouraging Early Biopotency Signals
We are extremely encouraged to receive this early data from the Gene Therapy Trial. Abeona Therapeutics provides update on initial subjects in Sanfilippo Type A Gene Therapy Trial, demonstrating encouraging early biopotency signals. Read more ... Learn more
Abeona Therapeutics Doses First Sanfilippo Patient With Gene Therapy
Exciting news to share! Abeona Therapeutics doses the first patient in Phase 1/2 Trial with ABO-102 Gene Therapy for patients with Sanfilippo Syndrome Type A (MPS IIIA). Read More >> http://www.marketwired.com/press-release/-2125579.htm ... Learn more
Big news for Sanfilippo Syndrome and Gene Therapy Research
PlasmaTech Biopharmaceuticals announces agreement to acquire Abeona Therapeutics, increasing the hope for Gene Therapy to reach more Sanfilippo ... Learn more